Cantor Fitzgerald reissued their buy rating on shares of Castlight Health (NYSE:CSLT) in a report released on Wednesday morning. They currently have a $5.00 price objective on the software maker’s stock.
“4Q17 results were solid. Revenue was $37 million vs. our estimate of $36.2 million. The company realized $0.5 million in non-recurring one-time payments related to non-renewed contracts. The adjusted loss per share was $0.04 vs. our estimate of a loss per share of 0.06.”,” the firm’s analyst commented.
Other equities research analysts also recently issued research reports about the company. Zacks Investment Research raised Castlight Health from a hold rating to a buy rating and set a $3.75 price objective for the company in a research report on Wednesday, January 31st. BidaskClub downgraded Castlight Health from a sell rating to a strong sell rating in a research report on Thursday, November 9th. Canaccord Genuity reaffirmed a buy rating and issued a $7.00 price objective on shares of Castlight Health in a research report on Thursday, October 26th. Finally, Chardan Capital lowered their price objective on Castlight Health from $6.50 to $6.30 and set a buy rating for the company in a research report on Thursday, October 26th. Three research analysts have rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. Castlight Health currently has a consensus rating of Hold and a consensus price target of $5.11.
Castlight Health (NYSE:CSLT) last announced its quarterly earnings data on Wednesday, February 21st. The software maker reported ($0.04) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.01. The business had revenue of $37.00 million during the quarter, compared to the consensus estimate of $36.36 million. Castlight Health had a negative return on equity of 32.57% and a negative net margin of 45.14%. The business’s revenue for the quarter was up 23.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.01) earnings per share. research analysts anticipate that Castlight Health will post -0.43 EPS for the current fiscal year.
Hedge funds have recently bought and sold shares of the business. Voya Investment Management LLC grew its position in Castlight Health by 25.4% during the second quarter. Voya Investment Management LLC now owns 26,929 shares of the software maker’s stock valued at $112,000 after acquiring an additional 5,453 shares during the period. MetLife Investment Advisors LLC purchased a new stake in Castlight Health during the fourth quarter valued at about $126,000. Nationwide Fund Advisors grew its position in Castlight Health by 49.5% during the second quarter. Nationwide Fund Advisors now owns 36,418 shares of the software maker’s stock valued at $151,000 after acquiring an additional 12,061 shares during the period. Stifel Financial Corp grew its position in Castlight Health by 12.3% during the second quarter. Stifel Financial Corp now owns 41,000 shares of the software maker’s stock valued at $171,000 after acquiring an additional 4,500 shares during the period. Finally, First Quadrant L P CA purchased a new stake in Castlight Health during the fourth quarter valued at about $167,000. 43.40% of the stock is owned by hedge funds and other institutional investors.
About Castlight Health
Castlight Health, Inc offers a health benefits platform that engages employees to make healthcare decisions, and enables employers to communicate and measure their benefit programs. The Company operates through cloud-based products segment. Its technology offering aggregates data and applies analytics to make healthcare data transparent.
Receive News & Ratings for Castlight Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castlight Health and related companies with MarketBeat.com's FREE daily email newsletter.